long-term results of 2 studies combining etoposide and adriamycin with cisplatin ( cav ) or cyclophosphamide ( ave ) in small cell lung cancer indicate a 2-year survival rate of 22 % and 18 % respectively .
C0010583
cyclophosphamide
C0108844
ave